Corticosterone

Identification

Name
Corticosterone
Accession Number
DB04652
Type
Small Molecule
Groups
Experimental
Description

An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)

Structure
Thumb
Synonyms
  • (11β)-11,21-dihydroxypregn-4-ene-3,20-dione
  • 11beta,21-Dihydroxy-4-pregnene-3,20-dione
  • 11β,21-dihydroxyprogesterone
  • 17-deoxycortisol
  • Kendall's compound B
  • Reichstein's substance H
Categories
UNII
W980KJ009P
CAS number
50-22-6
Weight
Average: 346.4605
Monoisotopic: 346.214409448
Chemical Formula
C21H30O4
InChI Key
OMFXVFTZEKFJBZ-HJTSIMOOSA-N
InChI
InChI=1S/C21H30O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h9,14-17,19,22,24H,3-8,10-11H2,1-2H3/t14-,15-,16+,17-,19+,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14S,15S,17S)-17-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UMineralocorticoid receptorNot AvailableHuman
UCorticosteroid 11-beta-dehydrogenase isozyme 1Not AvailableHuman
UNuclear receptor coactivator 1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
17-alpha-hydroxylase deficiency (CYP17)Disease
Corticosterone methyl oxidase I deficiency (CMO I)Disease
SteroidogenesisMetabolic
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia due to 21-hydroxylase DeficiencyDisease
21-hydroxylase deficiency (CYP21)Disease
Apparent mineralocorticoid excess syndromeDisease
3-Beta-Hydroxysteroid Dehydrogenase DeficiencyDisease
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAHDisease
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia due to 17 Alpha-hydroxylase DeficiencyDisease
11-beta-hydroxylase deficiency (CYP11B1)Disease
Corticosterone methyl oxidase II deficiency - CMO IIDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Corticosterone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Corticosterone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Corticosterone.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Corticosterone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Corticosterone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Corticosterone.Approved, Withdrawn
AldesleukinCorticosterone may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Corticosterone can be decreased when combined with Algeldrate.Approved, Experimental
AlmagateThe bioavailability of Corticosterone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Corticosterone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Corticosterone.Experimental
AloglutamolThe bioavailability of Corticosterone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Corticosterone.Experimental
AluminiumThe bioavailability of Corticosterone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Corticosterone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Corticosterone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Corticosterone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Corticosterone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Corticosterone.Approved
AmiodaroneThe serum concentration of Corticosterone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BCorticosterone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Corticosterone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Corticosterone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Corticosterone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Corticosterone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Corticosterone.Approved, Investigational
AprepitantThe serum concentration of Corticosterone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Corticosterone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Corticosterone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Corticosterone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Corticosterone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Corticosterone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Corticosterone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Corticosterone.Experimental
BendroflumethiazideCorticosterone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Corticosterone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Corticosterone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Corticosterone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Corticosterone.Experimental
Bismuth SubcitrateThe bioavailability of Corticosterone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Corticosterone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Corticosterone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Corticosterone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Corticosterone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Corticosterone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Corticosterone.Experimental
BumetanideCorticosterone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Corticosterone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Corticosterone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Corticosterone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideCorticosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Corticosterone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Corticosterone.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Corticosterone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Corticosterone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Corticosterone.Approved, Investigational
CeritinibCorticosterone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Corticosterone.Approved, Vet Approved
ChlorothiazideCorticosterone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Corticosterone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneCorticosterone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Corticosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Corticosterone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Corticosterone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Corticosterone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Corticosterone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Corticosterone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Corticosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Corticosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Corticosterone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Corticosterone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Corticosterone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Corticosterone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Corticosterone.Investigational
CyclopenthiazideCorticosterone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Corticosterone.Investigational
DaidzeinThe serum concentration of Corticosterone can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Corticosterone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Corticosterone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Corticosterone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Corticosterone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Corticosterone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Corticosterone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Corticosterone.Approved, Vet Approved
DienestrolThe serum concentration of Corticosterone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Corticosterone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Corticosterone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Corticosterone.Approved
DihydrotestosteroneCorticosterone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Corticosterone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Corticosterone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Corticosterone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Corticosterone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Corticosterone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Corticosterone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Corticosterone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Corticosterone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Corticosterone.Approved
EquolThe serum concentration of Corticosterone can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Corticosterone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Corticosterone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Corticosterone can be increased when it is combined with Estrone.Approved
Etacrynic acidCorticosterone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Corticosterone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Corticosterone.Experimental
Ethinyl EstradiolThe serum concentration of Corticosterone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Corticosterone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Corticosterone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Corticosterone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Corticosterone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Corticosterone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Corticosterone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Corticosterone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Corticosterone.Approved
FenthionThe risk or severity of adverse effects can be increased when Corticosterone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Corticosterone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Corticosterone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Corticosterone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Corticosterone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Corticosterone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Corticosterone.Experimental
FluoxymesteroneCorticosterone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Corticosterone.Approved, Investigational
FosaprepitantThe serum concentration of Corticosterone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Corticosterone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideCorticosterone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Corticosterone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Corticosterone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Corticosterone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Corticosterone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Corticosterone is combined with Ginkgo biloba.Approved, Investigational, Nutraceutical
GLPG-0492Corticosterone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Corticosterone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Corticosterone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Corticosterone.Experimental
HexestrolThe serum concentration of Corticosterone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Corticosterone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Corticosterone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Corticosterone.Approved, Investigational
HydrochlorothiazideCorticosterone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideCorticosterone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Corticosterone can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Corticosterone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Corticosterone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Corticosterone.Approved
IdelalisibThe serum concentration of Corticosterone can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Corticosterone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Corticosterone.Approved
IndapamideCorticosterone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Corticosterone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Corticosterone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Corticosterone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Corticosterone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Corticosterone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Corticosterone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Corticosterone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Corticosterone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Corticosterone.Withdrawn
ItraconazoleThe serum concentration of Corticosterone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Corticosterone.Experimental
KetoconazoleThe serum concentration of Corticosterone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Corticosterone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Corticosterone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Corticosterone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Corticosterone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Corticosterone.Experimental
LopinavirThe serum concentration of Corticosterone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Corticosterone.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Corticosterone.Approved, Investigational
LumacaftorThe serum concentration of Corticosterone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Corticosterone.Approved, Investigational
MagaldrateThe bioavailability of Corticosterone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Corticosterone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Corticosterone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Corticosterone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Corticosterone.Approved
Magnesium silicateThe bioavailability of Corticosterone can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Corticosterone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Corticosterone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Corticosterone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Corticosterone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Corticosterone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Corticosterone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Corticosterone.Approved
MesteroloneCorticosterone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Corticosterone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Corticosterone.Investigational, Withdrawn
MethallenestrilThe serum concentration of Corticosterone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Corticosterone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideCorticosterone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Corticosterone is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteroneCorticosterone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Corticosterone is combined with Metoclopramide.Approved, Investigational
MetolazoneCorticosterone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Corticosterone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Minaprine.Approved
MitotaneThe serum concentration of Corticosterone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Corticosterone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Corticosterone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Corticosterone.Experimental
MoxestrolThe serum concentration of Corticosterone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Corticosterone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Corticosterone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Corticosterone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Corticosterone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Corticosterone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Corticosterone is combined with Nalidixic Acid.Approved, Investigational
NandroloneCorticosterone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Corticosterone.Approved, Vet Approved
NefazodoneThe serum concentration of Corticosterone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Corticosterone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Corticosterone.Approved
NevirapineThe serum concentration of Corticosterone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Corticosterone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Corticosterone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Corticosterone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Corticosterone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Corticosterone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Corticosterone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Corticosterone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Corticosterone.Vet Approved
OxandroloneCorticosterone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Corticosterone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Corticosterone is combined with Oxolinic acid.Experimental
OxymetholoneCorticosterone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Corticosterone.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Corticosterone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Corticosterone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Corticosterone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Corticosterone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Corticosterone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Corticosterone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Corticosterone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Corticosterone.Approved, Investigational
PhenytoinThe serum concentration of Corticosterone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Corticosterone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Corticosterone is combined with Pipemidic acid.Experimental
PiretanideCorticosterone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Corticosterone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Corticosterone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Corticosterone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Corticosterone.Experimental
Polyestradiol phosphateThe serum concentration of Corticosterone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideCorticosterone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Corticosterone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Corticosterone.Experimental, Investigational
PrimidoneThe serum concentration of Corticosterone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Corticosterone.Experimental
PromestrieneThe serum concentration of Corticosterone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Corticosterone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Corticosterone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Corticosterone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Corticosterone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Corticosterone can be increased when it is combined with Quinestrol.Approved
QuinethazoneCorticosterone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Corticosterone is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Corticosterone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Corticosterone.Approved, Experimental, Investigational
RifabutinThe serum concentration of Corticosterone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Corticosterone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Corticosterone can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Corticosterone is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Corticosterone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Corticosterone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Corticosterone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Corticosterone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Corticosterone.Approved
SaquinavirThe serum concentration of Corticosterone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Corticosterone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Corticosterone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Corticosterone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Corticosterone.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Sitafloxacin.Experimental, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Corticosterone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Corticosterone.Investigational
St. John's WortThe serum concentration of Corticosterone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololCorticosterone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Corticosterone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Corticosterone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Corticosterone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Corticosterone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Corticosterone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Corticosterone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Corticosterone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Corticosterone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Corticosterone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Corticosterone.Approved, Withdrawn
TelithromycinThe serum concentration of Corticosterone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Corticosterone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Corticosterone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Corticosterone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Corticosterone.Approved
TestosteroneCorticosterone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Corticosterone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Corticosterone.Approved
TiboloneThe serum concentration of Corticosterone can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Corticosterone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Corticosterone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Corticosterone.Approved
TorasemideCorticosterone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Corticosterone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Corticosterone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Corticosterone is combined with Trichlorfon.Vet Approved
TrichlormethiazideCorticosterone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Corticosterone.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Corticosterone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Corticosterone.Investigational, Withdrawn
VoriconazoleThe serum concentration of Corticosterone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinCorticosterone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Corticosterone.Approved, Investigational
ZeranolThe serum concentration of Corticosterone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Corticosterone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Corticosterone.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Corticosterone is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB01547
KEGG Compound
C02140
PubChem Compound
5753
PubChem Substance
46504547
ChemSpider
5550
BindingDB
50170653
ChEBI
16827
ChEMBL
CHEMBL110739
HET
C0R
Wikipedia
Corticosterone
PDB Entries
1y5r / 2a3i / 4qf7 / 5l91 / 5l92

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.046 mg/mLALOGPS
logP2.09ALOGPS
logP2.02ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.86ChemAxon
pKa (Strongest Basic)-0.26ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity96 m3·mol-1ChemAxon
Polarizability38.79 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9926
Blood Brain Barrier+0.9451
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.771
P-glycoprotein inhibitor INon-inhibitor0.7124
P-glycoprotein inhibitor IINon-inhibitor0.7259
Renal organic cation transporterNon-inhibitor0.7122
CYP450 2C9 substrateNon-substrate0.8363
CYP450 2D6 substrateNon-substrate0.9143
CYP450 3A4 substrateSubstrate0.7636
CYP450 1A2 substrateNon-inhibitor0.9255
CYP450 2C9 inhibitorNon-inhibitor0.9211
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9593
CYP450 3A4 inhibitorNon-inhibitor0.8246
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8716
Ames testNon AMES toxic0.926
CarcinogenicityNon-carcinogens0.9497
BiodegradationNot ready biodegradable0.9454
Rat acute toxicity1.5110 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9403
hERG inhibition (predictor II)Non-inhibitor0.5206
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (2 MEOX; 2 TMS)GC-MSsplash10-0f9l-4920000000-13c56138ef34befd6786
GC-MS Spectrum - GC-MS (2 MEOX; 2 TMS)GC-MSsplash10-0f7c-4921100000-1d2ace868fd94080c88e
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-014i-1798000000-b39fe3c8aaf8f09d7cde
GC-MS Spectrum - GC-MSGC-MSsplash10-0f9l-4920000000-13c56138ef34befd6786
GC-MS Spectrum - GC-MSGC-MSsplash10-0f7c-4921100000-1d2ace868fd94080c88e
Mass Spectrum (Electron Ionization)MSsplash10-014i-8953000000-cdd7d53a6012a6eb3f28
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-0002-0009000000-81d0a5e41401c962645e
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-05fs-2910000000-7a585bd042169de23cfe
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0597-6900000000-4c9bb40342921d7ff55e
MS/MS Spectrum - EI-B (HITACHI M-80) , PositiveLC-MS/MSsplash10-014i-1798000000-e8ef26b439701fc96537
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0009000000-362accabc0136898e549
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0459000000-e31660ef75e29d9d9d78
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00fr-0941000000-1453953f7526fa9b8de6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00e9-0920000000-da03f39d4590a6248157
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00gi-0900000000-2ec9e62e392a282f6de4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0009000000-1db6d72ffc02b6efa63d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00ba-1964000000-d35661aaf929a1609854
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00dj-2920000000-b29d21507e63bc379164
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05fv-3900000000-8cd56447e4fa2da8c30b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0596-4900000000-0fdf5a6f27425f6540ba
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052f-6900000000-d6cd49302b0991f7a681
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00mo-9800000000-fcf363e8a5a69914ad88
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00mp-9600000000-493d479336ae32a15124
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-016u-9500000000-5e6760693c17aadb3f80
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0169000000-f22e1aba4ac6510b7c67
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0759000000-8c04fadb6bd7d3e86c28
MS/MS Spectrum - , positiveLC-MS/MSsplash10-05gi-3920000000-db0dc9413f5ca5cb69e3
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-4-steroids / 11-beta-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Alpha-hydroxy ketones / Secondary alcohols / Cyclic alcohols and derivatives / Primary alcohols
show 2 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-4-steroid / 3-oxosteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Oxosteroid / Delta-4-steroid
show 14 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3-oxo steroid, 11beta-hydroxy steroid, glucocorticoid, 20-oxo steroid, 21-hydroxy steroid, C21-steroid (CHEBI:16827) / Pregnane and derivatives [Fig], C21 steroids (gluco/mineralocorticoids, progestogens) and derivatives, Mineralocorticoids (C02140) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030186)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
11-beta-hydroxysteroid dehydrogenase [nad(p)] activity
Specific Function
Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the rea...
Gene Name
HSD11B1
Uniprot ID
P28845
Uniprot Name
Corticosteroid 11-beta-dehydrogenase isozyme 1
Molecular Weight
32400.665 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transcription coactivator activity
Specific Function
Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Involved in the coactivation of different nuclear re...
Gene Name
NCOA1
Uniprot ID
Q15788
Uniprot Name
Nuclear receptor coactivator 1
Molecular Weight
156755.44 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 11, 2007 11:49 / Updated on November 09, 2017 03:44